NEW YORK (GenomeWeb News) – Celera said today that the University of California, San Francisco has licensed the rights to use Celera’s KIF6 gene-related intellectual property to develop an in-house test for cardiovascular risk and statin benefit.
The agreement makes UCSF the first lab in the US besides Celera’s Berkeley HeartLab subsidiary to use the Celera discoveries.
Studies have shown an association between KIF6, which encodes a kinesin-like protein 6, and cardiovascular risk and statin benefit.
Under the agreement, UCSF will be allowed to develop and perform a test using KIF6 for three years in California.
Celera CEO Kathy Ordonez said in a statement that the agreement is “consistent with Celera’s strategy to make KIF6 testing broadly available and our efforts to drive our new genetic discoveries into routine personalized care for patients with risk for cardiovascular disease."
Financial terms of the agreement were not released.